Scintimammography Detects Tumors in Dense Breast Tissue
October 1st 1999NEW ORLEANS-Scintimam-mography utilizing a radionuclide already approved by the FDA for cardiac imaging has been shown to compare favorably with standard mammography in a new study presented at the 99th annual meeting of the American Roentgen Ray Society.
Risk Factors for Local Recurrence After Breast-Conserving Therapy
October 1st 1999NEW ORLEANS-In women treated with a breast-conserving approach for early-stage invasive breast cancer, “adequate” excision of the primary tumor is necessary to obtain optimal local tumor control. But what constitutes an adequate excision prior to radiation therapy, and what are the risk factors for local recurrence? A Harvard pathologist discussed this issue at the American Society of Breast Disease annual meeting.
New Brain Imaging Technique Cuts MR Scan Time in Half
October 1st 1999NEW ORLEANS-A new technique for magnetic resonance (MR) imaging can reduce brain scan time by half, according to a study from the Department of Radiology, University of Vienna, reported at the 99th annual meeting of the American Roentgen Ray Society. The new technique, T1-3D-echo-planar-imaging (EPI)-sequence, has diagnostic utility comparable to conventional T1-3D-gradient echo-sequence imaging, said lead investigator, Ahmed Ba-ssalamah, MD.
Laparoscopic Surgery Offers Important Benefits for Patients With Colorectal Disease
October 1st 1999Laparoscopic operating techniques are gaining wider acceptance among colorectal surgeons, as their efficacy is proven. These techniques offer patients the advantages of fewer complications, decreased need for postoperative narcotics, faster
Penn Cancer Center Sponsors Exhibit of Cancer Patients’ Art
October 1st 1999PHILADELPHIA-“Confronting Cancer Through Art” is a juried exhibition of inspirational artwork crafted by individuals who have been touched by cancer (see artwork). This year marks the second time that the University of Pennsylvania Cancer Center has sponsored this exhibit, which runs through October 31, 1999, at the Arthur Ross Gallery in Philadelphia. The first exhibit was presented in 1996.
Geffen Cancer Center Uses Western Medicine, Eastern Philosophy
October 1st 1999ARLINGTON, Va-Studies indicate that about half of cancer patients are now using complementary and alternative therapies, a finding that is motivating many medical oncologists to discuss such therapies with their patients and make recommendations about their use.
Tamoxifen Plus Goserelin as Adjuvant Therapy
October 1st 1999VIENNA, Austria-In a group of estrogen- or progesterone-positive breast cancer patients, combination endocrine treatment using goserelin (Zoladex) and tamoxifen (Nolvadex) significantly reduced the number of recurrences and increased disease-free survival, compared with CMF, after a median follow-up of 4 years, said Reimond Jakesz, MD, of the Department of General Surgery, University of Vienna, Austria.
New Developments in PET Aid Diagnosis, Rx of Cancers
October 1st 1999NEW YORK-Nuclear medicine-based imaging techniques are now being used to refine treatment strategies for cancer patients, with positron emission tomography (PET) at the forefront. Patients with complex cancers of the brain, head and neck, thyroid, and lung are now able to receive more refined and accurate diagnoses through new PET techniques, four speakers said at a nuclear medicine conference sponsored by Memorial Sloan-Kettering Cancer Center and Johns Hopkins University School of Medicine.
Participants in Chemotherapy Trials Incur Minimal Excess Cost
October 1st 1999Cancer patients enrolled in chemotherapy clinical trials at the Mayo Clinic in Rochester, Minnesota, incurred a 5-year average cost of $46,424, compared to $44,133 for matched control patients who were not trial participants, suggesting that
Court Says FDA Can’t Restrict Off-Label Drug Use Materials
October 1st 1999WASHINGTON-A federal judge has declared unconstitutional several sections of the Food and Drug Administration Modernization Act (FDAMA) that regulate the ability of pharmaceutical companies to distribute to physicians certain materials regarding off-label uses of drugs.
Be Alert for Other Possible Causes When Assessing CNS Side Effects of Opioids
October 1st 1999VIENNA, Austria-Among the CNS effects of opioids are cognitive failure, organic hallucinations, myoclonus, hyperalgesia, and severe sedation. “Regular, repeated assessments of cognition should be performed in patients taking opioids, and any changes should be evaluated by the physician to exclude other underlying etiologies,” Carla Ripamonti, MD, said at the World Congress on Pain.
Radiofrequency Ablation Shows Promise for Inoperable Liver Tumors
October 1st 1999Kim Jessup, MD, professor of surgery and director of the Gastrointestinal Oncology Program at the University of Pittsburgh Cancer Institute, is using radiofrequency ablation to dissolve tumors that have spread from the colon to the liver. According
Strang Program Integrates Standard and Complementary Therapies
October 1st 1999NEW YORK-A person-centered holistic approach to the practice of oncology involves the integration of current state-of-the-art Western therapies with nutritional supplementation and other less traditional methods, including meditation, music and sound therapy, and guided imagery techniques, said Mitchell L. Gaynor, MD, director of medical oncology and of the Integrative Medicine Program, Strang-Cornell Cancer Prevention Center, New York.
Interferon Significantly Affects Metabolism of Other Drugs Given to Cancer Patients
October 1st 1999Given to Cancer Patients Cancer patients undergoing therapy with interferonalfa-2b (IFN-a-2b [Intron A]) are possibly being overmedicated with the narcotics and antidepressants commonly administered with this agent, according to a University
Rate of Decline in AIDS Deaths Falls by More Than Half
October 1st 1999ATLANTA-AIDS deaths fell by 20% between 1997 and 1998, but this was a significantly smaller decline than the 42% fall in mortality that occurred between 1996 and 1997, according to data released by the Centers for Disease Control and Prevention (CDC).
Study Shows Direct Link Between H Pylori and Gastric Cancer
October 1st 1999ORLANDO-Researchers from Kure, Japan, reported on the first prospective study to show a direct connection between infection with Helicobacter pylori and the onset of gastric cancer. Their work, presented at the Digestive Disease Week meeting, builds upon epidemiologic research done in the early 1990s that strongly suggested such an association.
States Lag in Committing Tobacco Funds to Antismoking Efforts
October 1st 1999WASHINGTON-Only six of the states that settled their lawsuit with the tobacco industry last year have so far “provided enough new funding for truly comprehensive tobacco prevention and cessation programs,” according to a new report by the Campaign for Tobacco-Free Kids and the American Heart Association. The six states are Hawaii, Maryland, Minnesota, Vermont, New Jersey, and Washington.
NIH to Launch New On-Line Repository for Life Sciences Research
October 1st 1999BETHESDA, Md-The new year will bring a new and controversial source for obtaining access to new scientific studies in the life sciences. In January, the National Institutes of Health (NIH) will launch PubMed Central, a free on-line repository of research reports, found at http://www.ncbi.nlm.nih.gov/PubMed/.
Smoking Rates Fell Significantly in 1998, But Continued to Rise Among Young Adults
October 1st 1999ROCKVILLE, Md-Although cigarette smoking has remained relatively stable among youths age 12 to 17 since 1988, the percentage of young adults who smoke rose sharply between 1994 and 1998. According to a new government survey, 41.6% of Americans age 18 to 25 were cigarette smokers last year, up from 34.6% in 1994 and 40.6% in 1997.
Radiofrequency Ablation Used to Treat Liver Metastases
October 1st 1999BETHESDA, Md-Radiofrequency ablation (RFA) is being used to “cook” tumors where they lie and may be particularly useful for destroying liver metastases. This quick, nontoxic, relatively noninvasive approach will soon be tested in clinical trials, Bradford Wood, MD, of Georgetown University Medical Center and the National Institutes of Health, said in an interview.
PET, Lymphoscintigraphy Expanding Into the Clinic
October 1st 1999LOS ANGELES-“PET has arrived!” Edward Coleman, MD, said at a press conference held during the 46th annual meeting of the Society of Nuclear Medicine. Dr. Coleman, professor of radiology and director of the Nuclear Medicine Division, Duke University Medical Center, noted that “PET has expanded tremendously into the clinical environment.” He attributes this to the development of fluorodeoxyglucose (FDG) PET imaging and PET’s growing applications in oncology.
Modified Dendritic Cells Induce Immune Response
October 1st 1999PITTSBURGH-University of Pittsburgh researchers have shown that immature dendritic cells can be genetically modified to serve as an effective vehicle for presenting tumor antigens to the immune system. Such cells were shown to induce a significant and therapeutic tumor-specific immune response in an animal model.
Quality-of-Life End Points in Oncology Drug Trials
October 1st 1999Measurement of the quality of life (QOL) of patients, particularly those with cancer, has recently become a major scientific endeavor. The rapid growth of the hospice movement throughout the world during the past half-century has underscored the importance of palliation when a cure no longer seems possible.
Management of Menopausal Symptoms in the Cancer Patient
October 1st 1999The article by Castiel highlights the benefits and potential risks of estrogen replacement in cancer patients. For patients with malignancies that are not “estrogen sensitive,” adding hormone replacement therapy (HRT) to the therapeutic regimen can only improve quality of life.
Radiosensitization by Gemcitabine
Gemcitabine is a potent radiosensitizer in both laboratory studies and in the clinic. Initial laboratory studies showed that gemcitabine radiosensitizes a wide variety of rodent and human tumor cells in culture. Maximum
Stereotactic Radiosurgery for Brain Metastases
October 1st 1999Worldwide, approximately 100,000 patients have undergone stereotactic radiosurgery for a variety of intracranial lesions, of which brain metastases represent the most common treatment indication. This article summarizes the major issues surrounding the management of brain metastases, and also analyzes 21 independent reports of Gamma Knife– or linear accelerator–based radiosurgery, representing over 1,700 patients and more than 2,700 lesions. Variable reporting in the studies precludes a definitive, rigorous analysis, but the composite data reveal an average local control rate of 83% and median survival of 9.6 months, both of which are comparable to results in recent surgical reports. The most important prognostic factors for survival appear to be fewer than three lesions, controlled extracranial disease, and Karnofsky performance score (KPS). The exact impact of dose has not been clarified, but a dose-response relationship, especially for ³ 18 Gy, is emerging. The role of whole-brain radiotherapy remains unresolved. It may enhance local control but does not convincingly improve survival and, in some series, is associated with an increased risk of late complications. Chronic steroid dependence and increased intracranial edema do not appear to be common problems. This is an opportune time for the completion of ongoing randomized trials to validate these observations. [ONCOLOGY 13(10):1397-1409,1999]
Principles of Chemoradiation: Theoretical and Practical Considerations
Chemotherapy agents known to enhance the effects of radiation in preclinical studies have been used concurrently with radiotherapy in numerous clinical trials with the prospect of further enhancing radiation-induced